KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $43.7 billion.

  • Boston Scientific's Liabilities and Shareholders Equity rose 1085.92% to $43.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $168.1 billion, marking a year-over-year increase of 1112.66%. This contributed to the annual value of $43.7 billion for FY2025, which is 1085.92% up from last year.
  • Boston Scientific's Liabilities and Shareholders Equity amounted to $43.7 billion in Q4 2025, which was up 1085.92% from $42.7 billion recorded in Q3 2025.
  • Over the past 5 years, Boston Scientific's Liabilities and Shareholders Equity peaked at $43.7 billion during Q4 2025, and registered a low of $30.9 billion during Q1 2021.
  • Over the past 5 years, Boston Scientific's median Liabilities and Shareholders Equity value was $33.8 billion (recorded in 2023), while the average stood at $35.5 billion.
  • In the last 5 years, Boston Scientific's Liabilities and Shareholders Equity rose by 21.96% in 2022 and then skyrocketed by 1215.66% in 2025.
  • Quarter analysis of 5 years shows Boston Scientific's Liabilities and Shareholders Equity stood at $32.2 billion in 2021, then increased by 0.74% to $32.5 billion in 2022, then increased by 8.21% to $35.1 billion in 2023, then increased by 12.12% to $39.4 billion in 2024, then grew by 10.86% to $43.7 billion in 2025.
  • Its Liabilities and Shareholders Equity was $43.7 billion in Q4 2025, compared to $42.7 billion in Q3 2025 and $41.6 billion in Q2 2025.